Drug Trial Radar · NCT07743723
A Study of IOV-5001 in Adults With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
106
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Mar 2034
Study completion Mar 2044
Sponsor
- Lead sponsor
- Iovance Biotherapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1/2, multicenter, multi-cohort, open-label study of an autologous tumor-infiltrating lymphocytes (TIL) regimen with IOV-5001 in participants with previously treated advanced solid tumors
Conditions
- Advanced Solid Tumors
- Non-Small Cell Lung Cancer
- Triple Negative Breast Cancer (TNBC)
- Colorectal Cancer
- Head and Neck Squamous Cell Carcinoma
- Metastatic Solid Tumors
- Unresectable Solid Tumor
Interventions
IOV-5001Biological
IOV-5001 will be administered as 2 infusions, which will be administered in a hospital setting.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Safety AssessmentTime frame: Up to 30 days
- Phase 2: Efficacy Measured by Overall Response Rate (ORR)Time frame: Up to 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Weill Cornell Medicine-New York Presbyterian Hospital
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.